Allarity Therapeutics, Inc. Comprehensive Income
Allarity Therapeutics, Inc. (ALLR) reported Comprehensive Income of -$3.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$3.67M.
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$2.81M.
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$2.09M.
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$2.65M.
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$11.90M.
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$24.46M.
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$11.59M.
- Allarity Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$16.18M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.67M 10-Q · filed 2026-08-14 | -$6.48M 10-Q · filed 2026-08-14 | -$8.57M derived: sum of 3 quarters · filed 2026-08-14 | -$11.22M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$2.81M 10-Q · filed 2026-05-15 | -$4.90M derived: sum of 2 quarters · filed 2026-05-15 | -$7.55M derived: sum of 3 quarters · filed 2026-05-15 | -$11.70M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | -$2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$4.74M derived: sum of 2 quarters · filed 2026-03-30 | -$8.89M derived: sum of 3 quarters · filed 2026-08-14 | -$11.90M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$2.65M 10-Q · filed 2025-11-14 | -$6.80M derived: sum of 2 quarters · filed 2026-08-14 | -$9.81M 10-Q · filed 2025-11-14 | -$16.92M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | -$4.15M 10-Q · filed 2026-08-14 | -$7.16M 10-Q · filed 2026-08-14 | -$14.27M derived: sum of 3 quarters · filed 2026-08-14 | -$26.02M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$3.01M 10-Q · filed 2026-05-15 | -$10.12M derived: sum of 2 quarters · filed 2026-05-15 | -$21.88M derived: sum of 3 quarters · filed 2026-05-15 | -$23.65M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$18.87M derived: sum of 2 quarters · filed 2026-03-30 | -$20.64M derived: sum of 3 quarters · filed 2026-03-30 | -$24.46M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$11.75M 10-Q · filed 2025-11-14 | -$13.53M derived: sum of 2 quarters · filed 2025-11-14 | -$17.34M 10-Q · filed 2025-11-14 | -$18.72M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$1.77M 10-Q · filed 2025-08-15 | -$5.59M 10-Q · filed 2025-08-15 | -$6.97M derived: sum of 3 quarters · filed 2025-08-15 | -$11.51M derived: sum of 4 quarters · filed 2025-08-15 | ||
| 2024-03-31 | -$3.82M 10-Q · filed 2025-05-09 | -$5.19M derived: sum of 2 quarters · filed 2025-05-09 | -$9.73M derived: sum of 3 quarters · filed 2025-05-09 | -$12.14M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$5.91M derived: sum of 2 quarters · filed 2025-03-31 | -$8.32M derived: sum of 3 quarters · filed 2025-03-31 | -$11.59M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$4.54M 10-Q · filed 2024-11-14 | -$6.95M derived: sum of 2 quarters · filed 2024-11-14 | -$10.22M 10-Q · filed 2024-11-14 | -$11.90M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$2.41M 10-Q · filed 2024-08-05 | -$5.68M 10-Q · filed 2024-08-05 | -$7.37M derived: sum of 3 quarters · filed 2024-08-05 | -$13.04M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | -$3.27M 10-Q · filed 2024-05-14 | -$4.96M derived: sum of 2 quarters · filed 2024-05-14 | -$10.64M derived: sum of 3 quarters · filed 2024-05-14 | -$16.15M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$7.37M derived: sum of 2 quarters · filed 2024-03-08 | -$12.88M derived: sum of 3 quarters · filed 2024-03-08 | -$16.18M 10-K · filed 2024-03-08 | ||
| 2022-09-30 | -$5.68M 10-Q · filed 2023-11-14 | -$11.20M derived: sum of 2 quarters · filed 2023-11-14 | -$14.49M 10-Q · filed 2023-11-14 | -$31.49M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$5.52M 10-Q · filed 2023-08-14 | -$8.81M 10-Q · filed 2023-08-14 | -$25.81M derived: sum of 3 quarters · filed 2023-08-14 | -$28.26M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$3.29M 10-Q · filed 2023-05-11 | -$20.29M derived: sum of 2 quarters · filed 2023-05-11 | -$22.74M derived: sum of 3 quarters · filed 2023-05-11 | -$28.44M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$19.45M derived: sum of 2 quarters · filed 2023-03-13 | -$25.15M derived: sum of 3 quarters · filed 2023-03-13 | -$28.62M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | -$2.45M 10-Q · filed 2022-11-14 | $733.00K 10-Q · filed 2021-11-23 | -$8.15M derived: sum of 2 quarters · filed 2022-11-14 | -$11.63M 10-Q · filed 2022-11-14 | -$7.78M 10-Q · filed 2021-11-23 | -$12.12M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$5.70M 10-Q · filed 2022-10-07 | -$9.25M 10-Q · filed 2022-10-07 | -$9.67M derived: sum of 3 quarters · filed 2022-10-07 | -$10.04M derived: sum of 4 quarters · filed 2022-10-07 | ||
| 2021-03-31 | -$3.55M 10-Q · filed 2022-05-27 | -$3.97M derived: sum of 2 quarters · filed 2022-05-27 | -$4.34M derived: sum of 3 quarters · filed 2022-05-27 | |||
| 2020-12-31 | -$420.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | -$788.00K derived: sum of 2 quarters · filed 2022-05-17 | -$4.14M 10-K · filed 2022-05-17 | |||
| 2020-09-30 | -$368.00K 10-Q/A · filed 2022-05-17 | $170.00K 10-Q · filed 2021-11-23 | -$3.72M 10-Q/A · filed 2022-05-17 | -$2.66M 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |